ezetimibe has been researched along with Alloxan Diabetes in 5 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (20.00) | 29.6817 |
| 2010's | 3 (60.00) | 24.3611 |
| 2020's | 1 (20.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ahmad, S; Alatar, AA; Alvi, SS; Chaturvedi, CP; Faisal, M; Khan, MS; Nabi, R; Shah, A | 1 |
| Chen, CY; Chen, JW; Chen, JY; Huang, PH; Lin, SJ; Shih, CC | 1 |
| Chaturvedi, CP; Chaudhary, DK; Ecelbarger, CM; Godbole, MM; Kumar, P; Mohan, A; Singh, RS; Tiwari, S | 1 |
| Bantly, A; Hamamdzic, D; Mohler, ER; Moore, J; Parmacek, M; Putt, M; Rader, DJ; Shi, Y; Wilensky, RL; Yoder, M; Zhang, L | 1 |
| Choi, JM; Kim, BJ; Kim, L; Kim, SW; Kim, WJ; Lee, WY; Oh, KW; Park, CY; Park, SE; Park, SW; Rhee, EJ; Sohn, JH; Yang, SJ | 1 |
5 other study(ies) available for ezetimibe and Alloxan Diabetes
| Article | Year |
|---|---|
Ezetimibe attenuates experimental diabetes and renal pathologies via targeting the advanced glycation, oxidative stress and AGE-RAGE signalling in rats.
Topics: Animals; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Ezetimibe; Glycation End Products, Advanced; Maillard Reaction; Matrix Metalloproteinase 2; NF-kappa B; Oxidative Stress; Rats; Receptor for Advanced Glycation End Products; RNA, Messenger | 2023 |
Simvastatin pretreatment enhances ischemia-induced neovascularization and blood flow recovery in streptozotocin-treated mice.
Topics: Animals; Blood Flow Velocity; Collateral Circulation; Diabetes Mellitus, Experimental; Diabetic Angiopathies; Endothelial Progenitor Cells; Ezetimibe; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Ischemia; Male; Mice; Neovascularization, Physiologic; Nitric Oxide Synthase Type III; Phosphorylation; Recovery of Function; Regional Blood Flow; Simvastatin; Streptozocin; Time Factors; Vascular Endothelial Growth Factor A; Vasodilation | 2016 |
Greater efficacy of atorvastatin versus a non-statin lipid-lowering agent against renal injury: potential role as a histone deacetylase inhibitor.
Topics: Animals; Atorvastatin; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Ezetimibe; Histone Deacetylase Inhibitors; Histone Deacetylases; Kidney; Male; Rats; Rats, Wistar | 2016 |
Diabetes reduces bone marrow and circulating porcine endothelial progenitor cells, an effect ameliorated by atorvastatin and independent of cholesterol.
Topics: 1-Alkyl-2-acetylglycerophosphocholine Esterase; Animals; Antibiotics, Antineoplastic; Anticholesteremic Agents; Atorvastatin; Azetidines; Bone Marrow Cells; Cholesterol; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 1; Endothelial Cells; Ezetimibe; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pyrroles; Stem Cells; Swine; Vasodilation | 2009 |
Chronic administration of ezetimibe increases active glucagon-like peptide-1 and improves glycemic control and pancreatic beta cell mass in a rat model of type 2 diabetes.
Topics: Animals; Anticholesteremic Agents; Azetidines; Blood Glucose; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Ezetimibe; Glucagon-Like Peptide 1; Hyperglycemia; Insulin-Secreting Cells; Male; Rats; Rats, Inbred Strains | 2011 |